The FDA grants accelerated approval to dostarlimab for rectal cancer, Lilly reports one-year remission data for pediatric ulcerative colitis, and Johnson & Johnson shares longer-term fistula remission results for Tremfya.
News|Articles|October 13, 2025
Rentschler’s Time Capsule and How it Symbolizes European Biotech Progress
Author(s)Patrick Lavery
Listen
0:00 / 0:00
Key Takeaways
- Rentschler Biopharma's buffer media station in Germany represents its largest investment, enhancing European biotech competitiveness.
- The facility will be operational by 2028, featuring advanced infrastructure for buffer and media production.
A buffer media station that is currently under construction at Rentschler Biopharma headquarters is expected to contribute to the competitive biotechnology field across Germany and the rest of Europe.
Advertisement
The buffer media station, which Rentschler Biopharma said was scheduled to become fully operational by 2028, will be state-of-the-art, housed in a purpose-built, four-story building with a total area of 3400 square meters (36,600 square feet) (1). Production of buffer and media solutions will be supported by three media tanks and six buffer tanks, with the station connected to an in-house logistics system and piping systems for upstream and downstream processing.
Are other European companies making investments?
A select few other partnerships and expansions have taken shape across Europe in recent months. In August 2025, France-based
In September 2025,
What else has Rentschler Biopharma done in 2025?
Rentschler Biopharma began 2025 by saying, in late January, that it would be
On Oct. 6, 2025, Rentschler Biopharma
As part of the Oct. 6 announcement, Rentschler Biopharma said it would be attending the BioProcess International Asia conference, to be held in Kyoto, Japan from Oct. 20–22, 2025 (5). This event precedes CPHI Frankfurt 2025, scheduled for Oct. 28–30, 2025, at which Rentschler Biopharma COO
Winners will be announced at the opening ceremony of CPHI Frankfurt 2025, on Tuesday, Oct. 28.
References
1. Rentschler Biopharma.
2. Mirasol, F.
3. Mirasol, F.
4. Rentschler Biopharma.
5. Rentschler Biopharma.
6. Mirasol, F.
Advertisement
Related to this article
Accelerated approval for dostarlimab-gxly (Jemperli) pairs a single-arm phase 2 dataset with an FDA-authorized biomarker test and confirmatory requirements.
BMS's Dr Nathan Pennell outlines how biomarker testing barriers and trial diversity affect patient access to targeted oncology drugs.
In the phase 3 SHINE-2 trial, half of pediatric patients who responded to mirikizumab induction were in clinical remission at week 52. Lilly plans to file for a pediatric UC label expansion.
Guselkumab (Tremfya) sustained perianal fistula healing through 1 year in Crohn disease, with remission climbing to 35% in one FUZION dosing arm.
Roche will take ex-China development of Hansoh’s two preclinical ADCs and multiple programs against Roche-proposed targets once Hansoh completes global phase 1a trials. The deal includes $400 million upfront and more than $15 billion in potential milestones.
Cemiplimab's proposed EU regimen could cut Libtayo infusion visits from every 3 weeks to every 6 weeks, trimming infusion time by up to half.
Opus Genetics reports sustained vision gains with gene therapy, the FDA approves Roche’s Enspryng for at-home treatment of thyroid eye disease, and Estuary Biotherapeutics launches with $103 million to develop gene therapies for polycystic kidney disease.
Advertisement
Advertisement
Trending on BioPharm International
1
Roche, Hansoh Sign Second ADC Pact Covering Preclinical and Roche-Selected Targets
2
Estuary Biotherapeutics Launches With $103 Million for ADPKD Gene Therapy
3
FDA Approves Roche’s Enspryng as First At-Home Subcutaneous Treatment for Thyroid Eye Disease
4
Regeneron's Libtayo Earns CHMP Nod for Expanded EU Dosing
5